Ezzat S, Smyth H S, Ramyar L, Asa S L
Department of Endocrinology, University of Toronto, Ontario, Canada.
J Clin Endocrinol Metab. 1995 Mar;80(3):878-84. doi: 10.1210/jcem.80.3.7883846.
Basic fibroblast growth factor (bFGF) is a potent mitogenic and angiogenic factor that is known to regulate GH, PRL, and TSH secretion. Sequences within a bFGF gene family member have been detected in transforming DNA samples derived from human PRL-secreting tumors. Furthermore, elevated serum concentrations of bFGF have been noted in patients with multiple endocrine neoplasia-1. To further examine the significance of bFGF in sporadic human pituitary adenomas, we investigated the expression of bFGF by these tumors. Using an enzyme-linked immunoassay that recognizes all 16-24 kilodalton molecular mass forms of bFGF, we measured circulating serum concentrations in 21 patients with sporadic pituitary adenomas; they ranged from less than 0.5-84 pg/mL and declined following surgical adenomectomy. To confirm the pituitary source of this growth factor, we determined in vitro bFGF release from 43 adenomas (10 GH, 7 PRL, 10 ACTH, 14 gonadotrope adenomas/oncocytomas, and 2 silent subtype 3 adenomas). bFGF was present with wide variability (0.75-2100 pg/24 h.10(5) cells) in conditioned culture media of all adenomas examined. The adenohypophysial source of this growth factor was further demonstrated by the reverse hemolytic plaque assay. Variable bFGF messenger RNA expression was identified by the reverse-transcription polymerase chain reaction technique in 9 functional (2 PRL, 5 GH, 2 ACTH) and 7 nonfunctional (1 oncocytoma, 2 null cell, 2 gonadotrope, 2 Silent Subtype 3) adenomas examined. bFGF levels were unaltered in vitro following hypothalamic hormone stimulation/inhibition. The lack of a bFGF signal peptide sequence and hypothalamic hormone-independence suggest that secretion of this factor may be independent of pituitary hormone regulation. Immunocytochemistry failed to localize bFGF in tumors that released this factor in vitro, suggesting that storage of this peptide does not correlate with its synthesis and release. In conclusion, the heterogenous expression of bFGF suggests that it may play a specific and selective role in the tumorigenic process of some pituitary adenomas.
碱性成纤维细胞生长因子(bFGF)是一种强大的促有丝分裂和血管生成因子,已知其可调节生长激素(GH)、催乳素(PRL)和促甲状腺激素(TSH)的分泌。在源自人PRL分泌性肿瘤的转化DNA样本中已检测到bFGF基因家族成员内的序列。此外,在多发性内分泌腺瘤1型患者中已注意到血清bFGF浓度升高。为了进一步研究bFGF在散发性人垂体腺瘤中的意义,我们调查了这些肿瘤中bFGF的表达。使用一种能识别所有16 - 24千道尔顿分子量形式bFGF的酶联免疫测定法,我们测量了21例散发性垂体腺瘤患者的循环血清浓度;其范围为小于0.5 - 84 pg/mL,且在腺瘤切除术后下降。为了证实这种生长因子的垂体来源,我们测定了43个腺瘤(10个GH腺瘤、7个PRL腺瘤、10个促肾上腺皮质激素(ACTH)腺瘤、14个促性腺激素腺瘤/嗜酸性细胞瘤和2个沉默型3型腺瘤)的体外bFGF释放情况。在所检测的所有腺瘤的条件培养基中,bFGF的存在具有很大变异性(0.75 - 2100 pg/24 h·10⁵细胞)。反向溶血空斑试验进一步证明了这种生长因子的腺垂体来源。通过逆转录聚合酶链反应技术在9个功能性(2个PRL腺瘤、5个GH腺瘤、2个ACTH腺瘤)和7个无功能性(1个嗜酸性细胞瘤、2个无功能细胞腺瘤、2个促性腺激素腺瘤、2个沉默型3型腺瘤)腺瘤中鉴定出可变的bFGF信使核糖核酸表达。在下丘脑激素刺激/抑制后,体外bFGF水平未改变。缺乏bFGF信号肽序列以及不依赖下丘脑激素表明该因子的分泌可能独立于垂体激素调节。免疫细胞化学未能在体外释放该因子的肿瘤中定位bFGF,这表明该肽的储存与其合成和释放不相关。总之,bFGF的异质性表达表明它可能在某些垂体腺瘤的致瘤过程中起特定和选择性作用。